PharmaShots Weekly Snapshots (February 13 - 17, 2023)
Date: Feb 17, 2023 | Tags: Iveric Bio, Avacincaptad Pegol, Geographic Atrophy, Regulatory, US, FDA, NDA, Priority Review
Date: Feb 17, 2023 | Tags: ALX Oncology, Evorpacept, Urothelial Cancer, Clinical Trial, P-I, ASPEN-07 Study
Fresenius Kabi Launches Stimufend (biosimilar, pegfilgrastim) for Febrile Neutropenia in the US
Date: Feb 17, 2023 | Tags: Fresenius Kabi, Stimufend, biosimilar, pegfilgrastim, Febrile Neutropenia, Biosimilar, US
Date: Feb 17, 2023 | Tags: Applied Therapeutics, AT-007, Sorbitol Dehydrogenase Deficiency, Clinical Trial, P-III, INSPIRE Trial
Pfizer Reports P-III Trial Results of Zavegepant for the Acute Treatment of Migraine in Adults
Date: Feb 17, 2023 | Tags: Pfizer, Zavegepant, Migraine, Clinical Trial, P-III Trial
Date: Feb 17, 2023 | Tags: Capricor, Nippon Shinyaku, CAP-1002, Duchenne Muscular Dystrophy, Japan, HOPE-2 OLE study, Pharma
Arrowhead Gains Full Rights to ARO-PNPLA3 for Patients with Non-Alcoholic Steatohepatitis
Date: Feb 16, 2023 | Tags: Arrowhead, ARO-PNPLA3, Non-Alcoholic Steatohepatitis, Pharma, P-I Trial, TRiM platform
Henlius Reports the US FDA Acceptance of BLA for Proposed Biosimilar Trastuzumab HLX02
Date: Feb 16, 2023 | Tags: Henlius,Trastuzumab, HLX02, breast cancer, gastric cancer, Regulatory, US, FDA BLA
Date: Feb 16, 2023 | Tags: Merck, Aqilion, TAK1 Protein, autoimmune, inflammatory disease Pharma
Date: Feb 16, 2023 | Tags: Coherus, Junshi Bioscience, Toripalimab, Nasopharyngeal Carcinoma, Clinical Trial, P-III, JUPITER-02 Trial
Date: Feb 16, 2023 | Tags: BerGenBio, BGB324, bemcentinib, Non-Small Cell Lung Cancer, Clinical Trial, P-II Trial
Xilis Collaborated with MD Anderson to Advance Novel Technology and Advances Therapeutic Development
Date: Feb 16, 2023 | Tags: Xilis, MD Anderson, Novel Technology, NK cell therapy, MicroOrganoSphere technology, Pharma
Date: Feb 15, 2023 | Tags: Bavarian, Emergent BioSolutions, Vivotif, Vaxchora, typhoid fever, cholera, chikungunya, M&A, clinical trial, P-III, US, EU
Date: Feb 15, 2023 | Tags: Ipsen, Universite de Montreal, IRICoR, Oncology, Pharma
Date: Feb 15, 2023 | Tags: Seres Therapeutics, SER-109, Recurrent C. Difficile Infection, Clinical Trial, P-III, ECOSPOR IV Trial
Date: Feb 15, 2023 | Tags: Mirum, ivmarli, maralixibat, Cholestatic Pruritus, Progressive Familial Intrahepatic Cholestasis, Regulatory, sNDA, US, FDA
Ferring Launches Rebyota for the Prevention of Recurrence of C. diff Infection in Adults in the US
Date: Feb 15, 2023 | Tags: Ferring, Rebyota, Clostridioides difficile infection, US, Pharma, P-III, PUNCH CD3 trial
Date: Feb 15, 2023 | Tags: Sentia Medical Sciences, Neurocrine Biosciences, CRF Peptides, hypothalamic-pituitary-adrenal axis modulated diseases, Biotech
Date: Feb 14, 2023 | Tags: G1 Therapeutics, Trilaciclib, Colorectal Cancer, Clinical Trial, P-III, PRESERVE 1 Trial
Financial Strategies Acquisition Corp. to go Public via Austin Biosciences SPAC Merger for ~$166.3M
Date: Feb 14, 2023 | Tags: Financial Strategies Acquisition Corp, Austin Biosciences Corp, SPAC, Merger, ~$166.3M, M&A
Exelixis and Sairopa Receive the US FDA’s IND Clearance for ADU-1805 to Treat Advanced Solid Tumors
Date: Feb 14, 2023 | Tags: Exelixis, Sairopa, ADU-1805, Solid Tumors, Regulatory, US, FDA, IND
Date: Feb 14, 2023 | Tags: Cullinan Oncology, Harbour BioMed, HBM7008, CLN-418, US, solid tumors, Pharma
Date: Feb 14, 2023 | Tags: Merck KGaA, Bavencio, avelumab, Urothelial Carcinoma, Clinical Trial, P-III, JAVELIN Bladder 100 Trial
Date: Feb 14, 2023 | Tags: BMS, Exelixis, Opdivo, nivolumab, Cabometyx, cabozantinib, Renal Cell Carcinoma, Clinical Trial, P-III, CheckMate -9ER Trial
Date: Feb 13, 2023 | Tags: Astex, Cardiff University Medicines Discovery Institute, Neurodegenerative Diseases, Pharma
Scilex Acquires Rights for Elyxyb to Treat Migraine in the US and Canada
Date: Feb 13, 2023 | Tags: Scilex, Elyxyb, celecoxib, Migraine, US, Canada, M&A
Date: Feb 13, 2023 | Tags: Ocular Therapeutix, OTX-TKI, Wet AMD, Clinical Trial, P-I Trial
Date: Feb 13, 2023 | Tags: BMS, 2seventy bioAbecma, idecabtagene vicleucel, Multiple Myeloma, Clinical Trial, P-III, KarMMa-3 Trial
Date: Feb 13, 2023 | Tags: REGENXBIO, RGX-314, Wet Age-Related Macular Degeneration, Clinical Trial, P-II, Bridging Study
Pfizer Receives the US FDA’s Approval for Cibinqo (abrocitinib) sNDA to Treat Atopic Dermatitis
Date: Feb 13, 2023 | Tags: Pfizer, Cibinqo, abrocitinib, Atopic Dermatitis, Regulatory, sNDA, US, FDA, Approval
Related Post: PharmaShots Weekly Snapshots (February 06 - 10, 2023)
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.